Sanofi's $20B buyout of Genzyme pays off again with European OK for first Niemann-Pick drug

Zachary Brennan

Senior Editor

Sanofi CEO Paul Hudson has made clear his intention to develop new rare disease drugs and broaden his company’s offerings. That effort leaped forward on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi's $20B buyout of Genzyme pays off again with European OK for first Niemann-Pick drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Can Bill Anderson save Bayer?

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

How AI can address ongoing challenges in the life sciences industry

Sanofi's $20B buy­out of Gen­zyme pays off again with Eu­ro­pean OK for first Nie­mann-Pick drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi's $20B buyout of Genzyme pays off again with European OK for first Niemann-Pick drug